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Abstract
The high degree of conservation in microRNA from Caenorhabditis elegans to humans 
has enabled relatively rapid implementation of findings in model systems to the clinic. 
The convergence of the capacity for genomic screening being implemented in the 
prevailing precision medicine initiative and the capabilities of microRNA to address 
these changes holds significant promise. However, prostate, ovarian and breast cancers 
are heterogeneous and face issues of evolving therapeutic resistance. The transforming 
growth factor-beta (TGFβ) signaling axis plays an  important role in the progression of  
these cancers by regulating microRNAs. Reciprocally, microRNAs regulate TGFβ actions 
during cancer progression. One must consider the expression of miRNA in the tumor 
microenvironment a source of biomarkers of disease progression and a viable target for 
therapeutic targeting. The differential expression pattern of microRNAs in health and 
disease, therapeutic response and resistance has resulted in its application as robust 
biomarkers. With two microRNA mimetics in ongoing restorative clinical trials, the 
paradigm for future clinical studies rests on the current observational trials to validate 
microRNA markers of disease progression. Some of today’s biomarkers can be translated 
to the next generation of microRNA-based therapies.
Introduction
Precision medicine refers to leveraging larger scale somatic 
or genomic data in the informing medical decision-
making. Although the principles of precision medicine 
are extending into proteomics and metabolomics, a 
vast amount of patient data currently exists in the form 
of genetic material. The genome expresses more non-
coding RNA than the code for proteins. First recognized 
in 1993 in Caenorhabditis elegans, the noncoding RNAs, 
let-7 and lin-4 induced mRNA degradation (Lee  et  al. 
1993). The mature miR let-7 sequence, conserved from 
C. elegans to humans, is downregulated in multiple 
cancers, which highlights the significance of the 3’UTR 
region during gene regulation (Pasquinelli 2000, Vella et al. 
2004). MicroRNA (miR), most studied constituent of 
the non-coding RNAs, was termed to describe small 
(~22 nt) RNA regulators that influence gene functions 
(Lagos-Quintana et al. 2001). About 30–50% of all protein-
coding genes are possibly regulated by miRs in health and 
deregulated in disease. However, the exquisite tissue and 
developmental stage specificity of miR expression mean 
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that the regulation of miRs themselves can determine 
disease progression (Lagos-Quintana et al. 2001, Ruvkun 
2001, Calin  et  al. 2002). Calin and coworkers found 
that specific miR downregulation was associated with 
the incidences of B cell chronic lymphocytic leukemia 
(Calin et al. 2002). Now what was once recognized as the 
passive circulation of miR (found in all body fluids) is 
emerging as signaling molecules between cells and robust 
biomarkers of cancer progression and therapy response.
Gene regulation by miRs and reciprocal regulation 
of miRs have now been studied for over 15  years and 
extensively reviewed (Vidigal & Ventura 2015). Briefly, 
miRs are transcribed as pri-miRNAs that are cleaved by 
the Drosha/DGCR8 complex in the nucleus (Han  et  al. 
2004). The resulting hairpin-shaped pre-miRNA is further 
processed by Dicer in the cytoplasm (Zhang et al. 2002). 
The mature miRs employ the RNA-induced silencing 
complex (RISC) in the two mechanisms of gene regulation 
through mRNA degradation and translation inhibition 
(Fabian & Sonenberg 2012). The core of complex includes 
an argonaute protein for miR targeting and GW182 
protein to serve as the scaffold on the mRNA poly-A tail 
(Song et al. 2004, Hutvagner & Simard 2008). The degree 
of pairing between the miR and the target mRNA seems to 
be a determinant of the mechanism of regulation. Direct 
complementarity will induce target mRNA cleavage by 
argonaute and be immediately repressive. In the indirect 
or imperfect complementarity scenario, miRs bind to the 
3′ UTR prior to the poly-A tail to cause deadenylation 
of the mRNA. Loss of the poly-A tail leads to mRNA 
degradation. Imperfect complementation can additionally 
induce translational repression by blocking initiation of 
causing ribosomal drop-off. While the perfect pairing 
may be a more efficient repressor, there is a possibility 
that partial complementation may have a greater long-
term efficacy: an issue considered in therapeutic design. 
Although miRs can bind the ORF or 5′UTR to enhance 
translation (Orom et al. 2008, Lee et al. 2009), the 3′ UTR 
has been the target for miRs in the clinic. The regulation 
of the miR expression by hormones and cytokines will be 
further detailed here with a focus on the tumor and tumor 
associated microenvironment cell types.
The clinical application of miRs has rapidly matured 
from aspirational to now exploiting its diagnostic 
and therapeutic potential. We refer the reader to the 
comprehensive reviews describing the mechanisms 
of miR action (Wagner  et  al. 2014, Fendler  et  al. 2016, 
Masliah-Planchon et al. 2016). The direct role of miRs in 
cancer was made by the seminal publication of mutations 
in miR processing enzymes, DICER and DROSHA leading 
to ovarian cancer (Merritt  et  al. 2008). Now there are 
two observational clinical trials for ovarian cancer 
patients to determine the effects on miR expression in 
patients (ClinicalTrials.gov identifier: NCT01970696 
and NCT01572467). The pleotropic functions of miRs 
associated with transforming growth factor-beta/bone 
morphogenic protein (TGF-β/BMP) signaling will be used 
as an example as many of the miRs in current clinical 
utility seem to converge on this pervasive pathway. 
To appreciate the progress in the field, we need to start 
with one of the first mammalian miR identified, let-7. 
Its notoriety stems from KRas being one of its many 
targets. Although KRas is the most mutated gene in 
cancer, its activity is often elevated in the absence of 
mutations. Many miRs have been described to stimulate 
the RAS-MAPK pathway (miR-31, miR-143, miR-4689) 
(Hiraki et al. 2015, Chen et al. 2016, Edmonds et al. 2016). 
Regardless, in breast and ovarian cancer, let-7 is frequently 
downregulated, leading to increased KRas expression 
(Johnson et al. 2005, Dai et al. 2015). Since both of these 
cancers are commonly associated with activating Ras 
mutations, the loss of let-7 is even more significant in 
potentiating tumor progression. Although prostate cancer 
is not one of the cancers associated with Ras mutations 
through its tumor evolution, it is also associated with 
let-7 downregulation (Albino  et  al. 2016). The let-7 
example points to one of the many similarities the three 
cancers have. However, the rationale for active clinical 
trials using let-7 mimetics has a broader basis, and that is 
the fact that let-7 is a potent down regulator of HMGB1, 
c-myc, IL-6 and cyclin D2. Thus, therapeutic targeting of 
a single miR can potentially address a multitude of genetic 
and epigenetic changes that need to be addressed when 
dealing with the heterogeneous disease of each ovarian, 
prostate or breast cancer patient. However, as with any 
‘dirty drug’, antagonizing or mimicking a single miR with 
the many gene targets will result in unwanted side effects. 
Although the path from bench-to-bedside for miRs is 
not very different from any other oncology therapeutic 
or biomarker, the stark difference in miR mechanism-of-
action make it important to understand this topic in the 
era of precision medicine. The mandate of the Precision 
Medicine Initiative (NIH) is to ultimately have data-driven 
care for patients. Cancer genomic and RNAseq analysis of 
patients is the most developed unbiased high throughput 
means of patient screening. Accordingly, miRs are 
prominent biomarkers currently being validated in the 
clinic today to support diagnosis, prognosis or therapeutic 
efficacy. Further, miRs are beginning to reach the clinic as 
therapeutics themselves to address some of the changes 
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revealed by large-scale genomic analysis. However, it is 
important to remember miRs are generated by the cancer 
epithelia as well as its microenvironment. And in most 
cases, systemic administration of miR-based therapy will 
impact both cancer cells and its microenvironment. Thus, 
for miR studies to successfully translate to the patient, 
many cell types need to be considered (Sood et al. 2006).
Endocrine-related cancers of breast, prostate and 
ovaries will be the focus of this review. We discuss the 
mechanisms that regulate miRs during cancer progression. 
The clinical applications used to target miR functions 
increase precision, especially when standard therapies are 
less effective. Therefore, the urgency to understand the 
mechanisms by which miRs function during endocrine-
related cancers is reflected in the studies focused on miR 
signaling in the tumor microenvironment.
Rationale and pitfalls in targeting  
TGF-β/BMP signaling
AS TGF-β signaling is a master regulator of tumorigenesis, 
the tumor microenvironment, and metastatic progression, 
this pathway impacts many miRs with significant clinical 
potential. The broad range of pathways influenced by 
TGF-β signaling is reflected in nearly 40 members 
comprising the TGF-β gene family. These members 
include the three TGF-β ligands, growth differentiation 
factors (GDFs), inhibin, activin, nodal, endoglin, lefty 
and BMP ligands (Chang et al. 2002). The complexities of 
stromal–epithelial interactions involving TGF-β signaling 
manifest itself as a tumor suppressor in tumorigenesis, 
yet demonstrate tumor promoting activity in metastatic 
progression (Bhowmick et al. 2003, 2004, Taylor et al. 2011, 
Lebrun 2012, Smith & Kang 2013, Neuzillet et al. 2015). 
The cross-talk between TGF-β signaling and miR functions 
is based on an autoregulatory feedback loop observed 
(Butz  et al. 2011). The miR profiles of pituitary, prostate 
and breast cancer directly correlate with the disruptive 
functions of TGF-β. Several miRs, such as miR-21, miR-34a, 
and the miR-200 family cluster target TGF-β signaling in 
prostate, breast and thyroid cancer for their functions 
during tumor progression and promotion (Braun  et  al. 
2010, Shen  et  al. 2012, Chen  et  al. 2016) (Fig.  1). 
Interestingly, miR-21 can also in turn promote TGF-β1-
Figure 1
Modulation of the TGF-β/BMP signaling pathways by miRs. Validated targets in prostate, ovarian, and breast cancer are indicated by the corresponding 
colored ovals. miR targets identified in other tissues are indicated in grey ovals, as miR targets in one tissue may not be effective in another tissue. Only 
relevant miRs discussed in the paper are shown here and by no means depict all the TGF-β/BMP-associated miRs.
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induced epithelial to mesenchymal transdifferentiation 
(Li  et  al. 2016). Conversely, miR-200 expression down 
regulates known targets, including TGF-β2, that are 
particularly up regulated in many cancers (Benlhabib et al. 
2015). These few miRs serve just as examples of the cross-
regulation with the expression with TGF-β ligands.
Small molecule and neutralizing antibody-based 
antagonism of the TGF-β signaling axis is being pursued 
for multiple cancers. However, with the pleotropic roles 
of TGF-β it was not surprising that targeting the TGF-β 
ligands or receptors was associated with some unwanted 
side effects (Kulkarni  et  al. 1993, Anderton  et  al. 2011). 
It is possible that the specificity of a miR to a particular 
TGF-β ligand isoform or downstream effectors may limit 
some of these unwanted effects. Of these effectors, Smad2, 
Smad3 and Smad4 activate downstream transcription, 
but can be inhibited by STRAP and Smad7 activation 
endogenously. In addition, p38MAP kinase, AKT and 
RhoA are downstream of TGF-β in a cell-specific manner, 
with distinct and overlapping functions with Smad 
signaling (Bakin  et  al. 2000, Bhowmick  et  al. 2001a,b, 
2003). Smad2 and Smad3 are targeted by miR-155 and 
miR-200a, respectively (Kong et al. 2008, Park et al. 2008, 
Louafi  et  al. 2010, Ahn  et  al. 2012). Smad4, however, is 
targeted by miR-130a, miR-182, miR-205 and miR-483 
(Hao et al. 2011, Geraldo et al. 2012, Egawa et al. 2016). 
Identification of miRs that target TGF-β downstream 
effectors presents an advantage of specificity. However, 
since Smad4 is a shared effector of much of the broader 
TGF-β family of ligands it may share some of the same side 
effects faced with the TGF-β receptor kinase inhibitors. 
The function of such miRs, if used in a therapeutic 
function, would ultimately be dictated by the pleotropic 
nature of the Smad proteins. For example, Smads regulate 
transcriptional repressors (i.e., Snail, ZEB1/2) associated 
with EMT, binding to proteins required to produce 
miRs (i.e., p68) and influencing microenvironment 
components, such as cancer-associated fibroblasts (CAF).
The role of TGF-β during the biogenesis and 
maturation of miRs has been analyzed extensively in 
several disease states. Both TGF-β and BMP signaling 
regulate vascular integrity, acting through the vascular 
smooth muscle cells. Inhibition of either TGF-β or 
BMP signaling can disrupt vascular smooth muscle cell 
contractile phenotype. TGF-β/BMP-induced miR-21 had 
an essential role in the expression of smooth muscle 
specific genes CNN1 (calponin) and ACTA2 (α-smooth 
muscle actin) (Davis  et  al. 2008). The study found that 
TGF-β/BMP signaling regulated miR-21 expression by 
potentiating Smad1/5 or Smad2/3 to p68, a component of 
the DROSHA miR processing complex (Davis et al. 2008). 
This indicated that TGF-β/BMP signaling can regulate miR 
biosynthesis and not just transcription. It could mean 
that many miRs, besides miR-21, may be regulated in 
this fashion. On its own, this does not necessarily affect 
miR-based therapeutic design, but it would suggest that 
miRs that target the Smad proteins might affect the 
biosynthesis of other miRs. Due to the broad target range 
of any individual miR, it would require that all such Smad-
directed miR be tested for effects on other miRs.
miRs impact epithelial–mesenchymal 
transdifferentiation
Epithelial–mesenchymal transition (EMT) is a multi-
step process that regulates changes in cell morphology 
during embryogenesis, tissue development and tumor 
development (Kalluri & Weinberg 2009, Smith & 
Bhowmick 2016). One of the pro-tumorigenic roles of 
TGF-β signaling includes the potentiation of EMT (Oft et al. 
1996, Bakin et al. 2000, Bhowmick et al. 2001a,b, 2003). 
The miRs associated with EMT have some overlap with 
those discussed regulated by TGF-β. They are important to 
note due to their relevance to tumor aggressiveness and 
therapeutic resistance. Snail1 and Slug are transcriptional 
repressors of epithelial markers (E-cadherin, zona 
occludin) and upregulate the expression of mesenchymal 
genes (vimentin, N-cadherin) (Thiery et al. 2009). miR-9 
was found to downregulate Snail resulting in E-cadherin 
upregulation in melanoma to ultimately decrease growth 
and metastasis in vivo (Liu  et  al. 2012). Recently, miR-9 
and miR-200c was found to regulate PDGFR-mediated 
endothelial differentiation of triple negative breast cancer 
(D’Ippolito  et  al. 2016). miR-9 inhibition or miR-200c 
restoration, delivered peritumorally to MDA-MB-231 
xenografts, decreased the number of vascular lacunae, 
associated with breast tumor growth and dissemination 
(D’Ippolito  et  al. 2016). Another target of miR-200 is 
Zeb1/Zeb2 in the maintenance of cellular plasticity, a 
major hallmark of tumor cell morphology (Brabletz & 
Brabletz 2010). Interestingly, Zeb1 and Zeb2 bind to the 
E- and Z-box enhancer sequences of miR-200f promoter 
regions. In further cross-talk within the EMT regulators, 
Snail1 assists in the transcriptional repression of miR-200f, 
to enhance EMT (Diaz-Lopez  et  al. 2015). Importantly, 
miR-16 and miR-200 family members silences TGF-β 
signaling and blocks EMT (Brabletz & Brabletz 2010, 
Wang et al. 2014b, Tang et al. 2016). Individuals have the 
potential to influence several mRNA targets to regulate 
cancer progression (Davis-Dusenbery and Hata 2010). 
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However, in the study of their endogenous expression in 
cancer, families of miRs can be expressed concomitantly 
to have broad effects. When inhibiting a miR, therapeutic 
efficacy may be limited as other miR family members 
can compensate for the targeted miR. However, the use 
of specific miR mimetics would not be plagued by this 
issue. In a specific example, ectopic expression of miR-
200 members significantly reduced anaplastic thyroid 
carcinoma cell invasion in a ZEB1/ZEB2-dependent 
manner (Fig. 1) (Braun et al. 2010). As anaplastic thyroid 
carcinoma is a highly metastatic disease with poor 
prognosis, these findings suggest that a similar strategy 
for ovarian and triple negative breast cancer could be 
promising. It is important not to automatically assume 
that the regulation of a particular miR or its targets will be 
conserved from one tissue to another. However, findings 
in one tissue can suggest its testing in another tissue 
of interest. miR-10b is one such example where it was 
originally found to regulate EMT in a TGF-β dependent 
manner in breast cancer (Ma  et  al. 2007). Later, in 
independent mouse models, miR-10b was found to inhibit 
breast and pancreatic tumor metastasis (Moriarty  et  al. 
2010, Ouyang et al. 2014). Although in both reports EMT 
was attributed to be rational for the role of miR-10b on 
metastatic potential, the targets identified were entirely 
different. Since the targets were not cross-validated in 
the two tissues, there is no way to know if the common 
phenotypic and physiologic readout of miR action was a 
result of the same target or targets. Despites the caveats on 
the specificity of miR targets, the role of miRs on EMT and 
metastatic progression are well supported.
Addressing the tumor microenvironment 
with miRs
The concept of tumors being composed of disconnected 
‘rogue’ masses of malignant cells has long been 
abandoned. We now understand that tumors function like 
organs, and the components that make up tumors and the 
surrounding environment plays intimate roles in cancer 
progression. The interactions between miR-21 and Smad7, 
for example, have been shown to predict the formation 
of reactive skin cancer-associated fibroblasts (CAF) 
(Li et al. 2013b). As a target of miR-21, Smad7 translation 
is inhibited leading to an increase in cells with the CAF 
phenotype. However, when miR-21 is blocked or Smad7 
was overexpressed, TGF-β1-induced CAF formation was 
inhibited. The CAF and tumor epithelia of many cancer 
types rely on TGF-β signaling to mediate communication 
and increase tumor growth and potentiate therapy 
resistance (Coulouarn et al. 2008, Vonlaufen et al. 2008, 
Duner et al. 2010, Coulouarn & Clément 2014). However, 
due to the importance of the spatiotemporal nature of 
miR expression and action (Sood et al. 2006), we divided 
the discussion of specific miRs to the CAF associated with 
the three particular cancer types and immune cells in the 
next sub-sections.
Regulation of miRs within the prostate tumor 
microenvironment
The prostate luminal and basal epithelia are encircled 
by smooth muscle cells that differentiate into activated 
fibroblastic cells during cancer progression. The tumor 
inductive nature of CAF was first coined in the context 
of prostate cancer (Olumi et al. 1999). CAFs are a major 
component of the tumor stroma with undoubted 
cancer-promoting effects. Of particular interest, TGF-β 
signaling influences CAF ability to mediate oncogenic 
transformation of normal epithelial cells (Bhowmick et al. 
2004). The heterogeneous CAF populations can 
communicate within the stromal compartment in 
depositing certain ECM components and express 
cytokines/growth factors to facilitate cancer invasion 
and even instruct carcinoma cells to the site of metastatic 
invasion (Kiskowski et al. 2011, Li  et al. 2013b). In prostate 
cancer, the CAF often lose TGF-β receptor type II expression 
due to promoter methylation (Banerjee  et  al. 2014). 
However, we have found that there is a juxtaposition of 
TGF-β-responsive and -nonresponsive CAF in the prostate 
cancer microenvironment (Kiskowski  et  al. 2011). The 
loss of TGF-β responsiveness in the CAF can lead to the 
accumulation of DNA damage and expression of multiple 
growth factors (Coppe et al. 2008, Banerjee et al. 2014). 
P53-induced miR-34a was found to restore DNA integrity 
(He et al. 2007, Yamakuchi et al. 2008). Interestingly, miR-
34a expression in CAF has not been closely studied with 
respect to stromal DNA damage accumulation and its 
activation. Doldi and coworkers suggested that in prostate 
cancer the CAF could be activated in one of two ways: 
by IL-6 or TGF-β (Doldi et al. 2015). Both these cytokines 
can be sourced from the adjacent cancer epithelia in vivo. 
In this study, miR-133b emerged as a common mediator 
of CAF activation, as determined by the expression 
of markers such as, ACTA2, FAP, S100A4 and COL4A2 
(Doldi et  al. 2015). The expression of miR-409 by CAF 
was associated with prostatic tumor epithelial expansion 
and EMT (Josson  et  al. 2015). The surrounding prostate 
epithelia seemed to take up the miR-409, leading to 
increased tumor migration and invasion. Tumor growth 
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continued due to miR-409-directed inhibition of RSU1 
and STAG2 tumor suppressors. miR-15 and miR-16 are 
downregulated in prostate cancer CAF in the majority 
of 23 patients (Musumeci  et  al. 2011). These expression 
patterns inversely correlated with upregulation of FGF2 
and FGFR1, supportive of the tumor inductive nature 
of CAF. In addition to these miRs that potentially serve 
as biomarkers for prostate cancer progression, Shen and 
coworkers found that plasma miR-21, miR-20a, miR-
145 and miR-221 could risk stratify patients for tumor 
relapse (n = 82) (Shen  et  al. 2012). Patients with high or 
intermediate risk had particularly elevated expression of 
miR-21 (P = 0.047) and miR-145 (P = 0.011) compared to 
lower risk scores (Shen et al. 2012). Although the source 
of circulating miRs may be from either the cancer or 
the microenvironment, the capacity to affect the gene 
expression on cells that do not express the miR itself is eye-
opening when it comes to expression profiling tumors, as 
is the practice of precision medicine. It also means that 
therapeutic targeting of miRs needs to consider both the 
tumor epithelia and its microenvironment.
Regulation of miRs within the ovarian tumor 
microenvironment
All three major cell types of the ovaries (epithelial, germ 
and stromal cells) can develop malignancies. Although 
the epithelial tumors are the most common, the 
contribution of CAF in this disease is evident by shear 
bulk and prevalent cross-talk. The fibrotic scarring and 
development of fibroblast populations closely related 
to the epithelial tumor cells seem to correlate with miR 
functions. It has been difficult to stratify serous ovarian 
cancer. The pathologic similarities of this common ovarian 
cancer type do not reveal the level of chemoresistance of 
these tumors. However, a set of ECM and ECM remodeling 
proteins (10-gene signature: AEBP1, COL11A1, COL5A1, 
COL6A2, LOX, POSTN, SNAI2, THBS2, TIMP3 and VCAN) 
were identified as associated with poor overall survival 
(Cheon et al. 2014). The signature genes are TGF-β regulated 
and their involvement with miR functions is broad. MMPs, 
TIMPs and Smads have a defined interplay with miRs in 
cancer metastasis. Examining miR silencing of Smad3 by 
miR-200a, for example, resulted in downregulation of a 
different set of ECM proteins (i.e., collagen I, collagen IV, 
fibronectin, PAI-1 and α-smooth muscle actin) (Wang et al. 
2011). Careful interrogation of the ovarian cancer-
associated signature resolved COL11A1 to be a determinant 
of lethal disease progression (Cheon et al. 2014). COL11A1 
expression is regulated by a TGFβ target transcription 
factor, SOX9. SOX9 is a direct target of miR-145 and is 
found to regulate COL11A1 expression (Yang et al. 2011). 
As the primary tumor microenvironment can predispose 
the cancer epithelia for metastasis, the metastatic site 
itself clearly has an influence on the adaptability of the 
tumor cells (Bhowmick 2012). One way the secondary site 
can be made adaptive to the tumor cells is the transport 
of cancer-derived miRs via exosomes. A seminal example 
of this phenomenon was described for pancreatic cancer 
metastasis to the liver (Hoshino  et al. 2015). As another 
highly metastatic tumor type, ovarian cancer frequently 
spreads to the omentum adipose fat. In one example, the 
omental fat cells and associated CAF were found to express 
exosomes containing miR-21 (Au Yeung  et  al. 2016). 
miR-21 is induced by many cytokines including TGF-β and 
is associated with collective migration (Dean et al. 2015). 
The ovarian cancer epithelia were found to accept these 
miR-21 containing exosomes to support chemoresistance 
by directly silencing its target, APAF1 (Au Yeung  et  al. 
2016). Metastatic breast and prostate cancer cells also 
overexpress miR-21. miRs have been identified in 
exosomes and microvesicles derived from several tissues, 
plasma, saliva and urine to support a means of cell to 
cell transfer and the viability of the use of exosomes as 
biomarker capsules. Thus, it is fitting that therapeutic 
microvesicles can be generated to transfer miR cargo to 
counter metastatic progression.
Regulation of miRs within the breast tumor 
microenvironment
miRs identified in CAF can regulate the expression 
of paracrine factors. Dysregulated miRs in breast CAF 
included upregulation of miR-221, miR-31, and miR-221 
with the downregulation of miR205, miR-200b, miR-200c, 
miR-141, miR-101, miR-342, let-7g and miR-26b affecting 
all aspects of cell differentiation and paracrine regulation 
(Zhao  et  al. 2012). Although in the epithelia miR-205 
and miR-200 family members (miR-200c, miR-200b and 
miR-141) are associated with EMT progression, in 
fibroblastic cells they clearly have a different function. 
In the breast CAF, miR-200 family members seem to 
contributed to ECM remodeling through the expression 
of fibronectin and lysyl oxidase to potentiate cancer 
epithelial invasion (Tang  et  al. 2016). In the absence of 
somatic mutations in the CAF population, epigenetic 
changes in the form of DNA methylation and miR 
expression can dictate the fate of adjacent epithelia. 
However, the redundancy of miR-200 downregulation in 
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both the epithelial and stromal compartments is highly 
supportive of using miR mimetic of this species.
We have discussed examples where the miR itself can 
act in a paracrine manner. Another example of this for 
breast cancer was identified in exosomes expressed by 
CAF recently. Upregulation of miR-133b in CAF was found 
to travel via gap junction proteins into breast cancer 
epithelia, where it has anti-apoptotic and pro-growth 
molecule with oncomiRs properties (Katakowski  et  al. 
2010, Xin  et  al. 2012). Interestingly, miR-133b transfer 
could be limited by the use a gap junction inhibitor 
(Xin  et  al. 2012), revealing a novel way of countering 
the miRs identified in primary tumors to prevent future 
metastatic progression. Incidentally, miR-133b was also 
identified to be a poor prognostic indicator in prostate 
cancer, in causing further aggressive behavior (Li  et  al. 
2014). For prostate cancer, miR-133b was of epithelial 
origin. But the same miR-133b expressed by breast cancer 
CAF suggests that an individual miR can have a role in the 
cancer and its microenvironment regardless of its source.
miR regulation in immune system signaling
The introduction of checkpoint inhibitors in the 
armamentarium against cancer has caused us to 
reevaluate our understanding of T cell biology, in terms 
of clinical applications. Now, companion biomarkers and 
combination therapy candidates are a focus in many labs. 
miRs can play an important role in both these fronts. As 
TGF-β is a known immune-suppressor, it is not surprising 
that it has a central role in adaptive and innate immune 
function. The Smad2 silencing by miR-155 can promote 
B-cell activation as well as enable CD4 T cells mature to 
TH17 and TH1 cells (Mehta & Baltimore 2016). miR-155 
is also critical in cells of the myeloid lineage. miR-155 
expression is upregulated by NF-κB signaling, downstream 
of toll-like receptor activity to drive dendritic cells and 
macrophage differentiation (O’Connell et al. 2007). Smad4-
mediated stimulation of granulocyte differentiation by 
TGF-β is tempered by miR-130a expression (Hager  et  al. 
2011). The miR-34a is a member of miR-34 family that 
target TGF-β/Smad4 signaling in T-regulatory (Treg) cell 
tumor recruitment. Yang and coworkers demonstrated 
that miR-34a downregulation in liver tissues results in 
CCL22 expression for the recruitment of Treg-mediated 
escape from immune surveillance (Yang  et  al. 2012). 
Numerous publications on miR-34a suggesting its role as 
a tumor suppressor, demonstrate a reduction in several 
cancer types including breast, ovarian and prostate cancer 
(Corney et al. 2010, Peurala et al. 2011, Benassi et al. 2012). 
Analysis of miR-34 in human epithelial ovarian cancer 
showed that there was a 100% decrease in miR-34, and a 
72% decrease in miR-34b*/c in the context of p53 mutation 
(Corney et al. 2010). Wild type p53 correlated with a 93% 
decrease in miR-34 in ovarian cancer cells. Clinically, 
stage III and stage IV tumors were analyzed where 
reduced miR-34 was significant (P = 0.0029, P = 0.0171, 
respectively). Interestingly, miR-34a downregulation is 
frequently regulated by promoter methylation in cancer 
cells. These counter acting epigenetic regulations impact 
the expression of endogenous oncogenes (e.g., MYC) as 
well as exogenous immune infiltration (Benassi  et  al. 
2012, Yang  et  al. 2012). The confounding epigenetic 
mechanisms need to be considered before long-term 
clinical use of miR-based therapeutics is in practice.
Clinical applications of miRs in ovarian, 
prostate and breast cancer
miRs are currently part of many trials examining genomic 
signatures to contend with the issue of patient selection 
to identify companion biomarkers for conventional 
therapeutics. As miRs are increasingly examined in 
patients, the importance of not making generalizations 
of a miR being oncogenic or tumor suppressor is clear. 
Further sources of variability in miR detection in bodily 
fluids can be associated with factors such as diet, age and 
circadian rhythms. Yet, in multiple independent studies 
miR-200 family was upregulated in metastatic breast 
and prostate cancers (Lin et al. 2014, Taylor et al. 2016). 
However, miR-200 family members have been reported to 
be both up- as well as downregulated in ovarian cancer 
(Park et al. 2008, Kan et al. 2012). Notwithstanding, miRs 
are attractive due to their stability and conservation 
among species (Chen  et  al. 2008). miRs gain their 
extraordinary stability from their small size (20–24 nt) 
being less exposed to degradation (even during FFPE 
sample processing), encapsulated in protective exosomes 
or microvessicles and most commonly its association with 
RNA binding proteins. Exosome-free miRs associated with 
argonaute proteins make up much of what is detectable 
in circulation (Turchinovich  et al. 2011). It is not just a 
coincidence that miRs have diagnostic value for cancer 
patients, but rather that miRs are frequently located at 
fragile chromosomal sites associated with cancer hotspots 
(Calin & Croce 2006). Accordingly, screening both free and 
exosome-associated miRs by high-throughput sequencing 
platforms have revealed changes in breast, prostate and 
ovarian cancer patients.
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RNA-based therapies have been tested for twenty years, 
with antisense oligonucleotides having the longest track 
record in the clinic. As of 2016, eight of those therapies 
had reached phase III clinical trials. Short interfering RNAs 
(siRNAs) have been used in the clinic, but none have reached 
phase III yet. However, there are only two current trials using 
miRs in interventional trials. In these phase I studies, miR 
mimetics have been used to restore miR-34 (MRX34) and 
miR-16 (TargomiRs) activity. Some of the roles of miR-34 
have already been discussed, as one of its targets is Smad4. 
As previously described, miR-16 inhibits TGF-β-induced 
EMT by silencing p-FAK and p-Akt expression, disrupting 
NF-κB and Slug transcriptional activity (Wang et al. 2014b). 
Although it is not possible to assess the clinical efficacy of 
the miR-based therapeutics at this stage, these two drugs 
were well tolerated with minimal inflammatory side 
effects. Regardless, it should be noted that the FDA has not 
approved an RNA-based drug to date. The reasons for the 
low success rate are not entirely clear, but a critical hurdle 
of therapeutic delivery seems to have improved. The lessons 
learned through the long history of antisense RNA-therapy 
are evident, as both miR trials use nanoparticle-based 
formulations to enhance drug availability. In the near term, 
we may also see further improvements in tissue targeting 
and sustained release of miRs or anti-miRs encapsulated 
in nanoparticles conjugated to antibodies or peptides. 
However, with about a 7% likelihood of FDA approval of 
any oncology drug, many of the challenges are not unique 
to RNA-based therapy (Hay  et  al. 2014). The need for 
understanding tumor heterogeneity, mechanisms of host–
tumor interaction, and patient selection are only a few 
obvious issues that we still need to address.
miRs in prostate cancer patient care
Prostate cancer is the most common non-cutaneous 
cancer in men and, next to lung cancer, is the second 
leading cancer killer in men. Improvements in survival 
from the disease have been due to advances in first 
line interventions (surgery and radiation) as well as 
newer antagonists to the androgen signaling axis. Yet, 
metastatic prostate cancer has no cure as resistance to 
androgen antagonists are inevitable, and taxane therapy 
was approved by the FDA for providing an increase in 
three months of overall survival (Petrylak  et  al. 2004, 
Tannock et al. 2004). Thus, markers for patient selection 
and sensitizing agents for current therapies are a focus in 
the field. Currently, there are a number of clinical trials 
that aim to analyze the miRs in prostate cancer and treat 
the malignancies by using miRs, detailed in Table 1. As 
an example, the Medical College of Wisconsin conducted 
a study to identify exosomal miRs from peripheral 
blood of prostate cancer patients with systemic disease 
to predict response to androgen deprivation therapy. 
In the study, they gathered blood sample at the time of 
treatment, 3 months post-treatment and upon disease 
progression to determine changes on disease response 
(ClinicalTrials.gov Identifier: NCT02366494). The study 
further aims to compare exosomal RNA levels between 
groups of patients who have relapsed as opposed to those 
in remission within 2  years of treatment. In a phase II 
study, expression levels of circulating miRs are being 
validated as a biomarker for sensitivity to abiraterone 
acetate (androgen synthesis inhibitor) and to predict 
metastatic prostate cancer progression (ClinicalTrials.
gov identifier: NCT01503229). These observational and 
interventional study examples would help in the process 
of decision-making for patient care. One could envision 
such a set of markers complementing imaging techniques 
in identifying metastatic status. Most prostatic metastasis 
is invisible to current imaging techniques in the early 
stages. If stable miRs could predict such an eventuality, it 
could suggest the use of chemotherapy, such as a taxane, 
at a time when it could appreciably alter overall survival.
Another set of observational trials attempts to identify 
therapeutic efficacy by measuring dynamic changes in the 
Table 1 Prostate cancer clinical trials involving miRs.
Trial reference Study type Institution Trial title
NCT02366494 Observational Medical College of Wisconsin MicoRNAs to predict response to androgen 
deprivation therapy
NCT01503229 Interventional University of Washington Abiraterone acetate in treating patients with 
metastatic hormone-resistant prostate cancer
NCT01220427 Observational Wuerzburg University Hospital microRNA expression profiles in high risk 
prostate cancer
NCT02471469 Observational Radboud University Personalizing enzalutamide therapy by 
understanding the relation between tumor 
mRNAs, miRNAs and treatment response
NCT02391051 Interventional University of Erlangen-Nürnberg Medical School Focal brachytherapy in patients with selected 
‘low-risk’ prostate cancer – a phase-II-trial
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expression of specific miRs in circulation in response to 
androgen deprivation therapy. A current study underway 
at Radboud University (Nijmegen, Netherlands) explores 
the possibility of dosing enzalutamide therapy (androgen 
receptor antagonist) based on reduction in a panel of 
select miRs to assess treatment response (ClinicalTrials.
gov identifier: NCT02471469). A phase II trial conducted 
by University of Erlangen-Nürnberg Medical School 
(Nürnberg, Germany) explores the feasibility and toxicity 
of focal brachytherapy in 50 patients with low-risk prostate 
cancer (ClinicalTrials.gov identifier: NCT02391051). The 
secondary outcome of this study is to correlate miR-375 
and miR-141 to visible efficacy of the radiation therapy. 
This secondary endpoint is supported by a number of 
previous clinical studies including, one where miR-21, 
miR-141 and miR-221 was detected in the plasma of a 
prostate cancer cohort of 51 patients (locally advanced or 
metastatic) had higher expression compared to 20 healthy 
controls (Yaman Agaoglu et al. 2011). It turned out that 
miR-21 helped distinguish between healthy and prostate 
cancer patients, but miR-141 (miR-200 family member) 
enabled distinction between localized and metastatic 
subjects. A related study screening 667 abundant miRs 
in the serum of prostate cancer patients identified 
miR-375 and miR-141 to be closely associated with disease 
progression (ClinicalTrials.gov identifier: NCT02391051) 
(Brase  et  al. 2011). The study therefore proposed that 
circulating miR-375 and miR-141 can be used as a non-
invasive biomarker for tumor progression (Brase  et  al. 
2011). The near-term ramifications of determining 
treatment efficacy is to be able to change therapies to 
one that may be effective for the patient and not subject 
him to the side effects associated with an ineffective drug. 
However, it may also suggest an opportunity to provide 
a combination therapy of a particular miR mimetic with 
a conventional intervention. For those patients that 
do not manifest a drop in miR-141 with radiation, an 
anti-miR-141 could be supplemented with radiation. As 
the use of miRs for prostate cancer therapeutics is at a 
nascent stage, results from such observational trials could 
lead back to the bench to test potential complementary 
therapeutic approaches pre-clinically.
The first-in-man miR-based therapeutic trial, MXR34 
(NCT01829971), delivered in a liposomal nanoparticles was 
in part based on the important work by Liu and coworkers 
showing that systematic delivery of miR-34a reduced 
prostate tumor and metastasis in mice (Table 1) (Liu et al. 
2011). As CD44 was validated as a target for miR-34a in 
the publication, it was attributed to preventing prostate 
cancer metastasis and regeneration (Liu  et  al. 2011). 
CD44 silencing in LAPC4 cells prevented lung metastasis 
and expansion of orthotopic tumors (Liu  et  al. 2011). 
Since that study, we have a better appreciation of the 
pro-metastatic properties of hyaluranon (a CD44 ligand) 
(Hiraga  et  al. 2013). However, considering other known 
targets of miR-34a, such as Notch, CDK4 and CyclinD1, 
it is difficult to attribute a miR’s systemic effects in vivo 
on any one target. As a direct target of p53, miR-34 
targeting can potentially have effects on any number of 
cancer types. But, the highest levels of miR-34a are in the 
ovary, prostate and testes. Thus, its downregulation in the 
respective cancers in those organs would likely benefit the 
greatest from a miR-34 mimetic like MXR34. However, as 
with all miRs, the targets are highly dependent on the cell 
type. For the tested prostate cells, CD44 has emerged as the 
reproducible target of miR-34a. However, it is important 
to note that the current MXR34 study in unresettable 
liver cancer patients where delivery system and potential 
off-target effects will be revealed. Liver cancer was the 
chosen disease for the MRX34 study since the liposomes 
that contain the double-stranded RNA payload tend to 
accumulate in liver tissues. For prostate targeting, the 
lyposomes maybe functionalized with PSMA (prostate 
specific membrane antigen) or other such agent. MXR34 
tries to address the two primary obstacles in gene therapy, 
tissue-specific delivery and cellular uptake.
miRs in ovarian cancer patient care
The most lethal form of gynecologic malignancy is 
ovarian cancer, with a dismal 44% five-year survival rate. 
Over 200,000 women around the world are diagnosed 
with ovarian cancer each year and cancer antigen 125 
(CA-125) can only detect late stage disease with little 
predictive value as to therapy response or relapse. 
Unfortunately, since three-fourths of the patients present 
with advanced disease, surgical cytoreduction and 
platinum/taxane-based chemotherapy are among the 
first lines of intervention. Benson and coworkers first 
reported that the concentration of circulating miRs is 
altered after administration of carboplatin and decitabine 
chemotherapy regime in platinum resistant recurrent 
ovarian cancer patients, in a phase II clinical trial of 
18 subjects (Benson  et  al. 2015). A tumor suppressive 
role for miR-148b-5p has been suggested in multiple 
solid tumors (Song  et  al. 2011, Zhao  et  al. 2013). The 
phase II trial showed reduced circulating miR-148b-5p 
was associated with longer progression free survival on 
chemotherapy (Benson et al. 2015). This study suggested 
that chemotherapy induced miRs concentration changes 
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could be used as a prognostic biomarker of therapeutic 
response in ovarian cancer patients. A similar decision 
enabling miR was described for prostate cancer. However, 
for a disease that can progress rapidly, miR-448-5p could 
be especially important to limit ovarian cancer recurrence 
(Kim et al. 2010).
EphA2 is a well-recognized marker and evolving 
therapeutic target for multiple cancers including ovarian 
and breast cancer. EphA2 is part of a receptor family 
associated with epithelial–endothelial interaction via 
juxtacrine signaling by Eph ligands. Interestingly, miR-
520d-3p with EphA2 is an independent prognostic marker 
for serous ovarian cancer (Nishimura  et al. 2013). Many 
mechanisms of EphA2 targeting involving peptide- and 
antibody-conjugates of chemotherapy as well as CAR-T 
cell therapy have had preclinical promise (Kiewlich et al. 
2006, Chow et al. 2013, Wang et al. 2013). SiRNA-mediated 
silencing of EphA2 has reduced ovarian tumor growth 
in mouse models (Landen  et  al. 2005). More recently, 
miR-520d-3p mimetic was found to synergize with 
EphA2 siRNA to reduce ovarian tumor size and invasive 
capacity (Nishimura  et  al. 2013). Both complementary 
therapeutic platforms depend on AGO2-RISC complex to 
downregulate EphA2 expression.
TargomiRs is the second of the two miR mimetics 
currently in clinical trials (Australian New Zealand Trial 
# ACTRN12614001248651). It is being tested for safety 
in late stage pleural mesothelioma and non-small cell 
lung cancer subjects. TargomiRs are EGF receptor-targeted 
antibody conjugated to minicells containing a miR-16 
mimic. The mimic is a double-stranded RNA molecule 
in a bacteria-based nanoparticle (minicell). As previously 
mentioned, miR-16 is implicated as a tumor suppressor for 
many cancers. However, there are compelling preclinical 
reports in which the ovarian cancer models were treated 
with cisplatin alone or in combination with miR-15a 
and miR-16 mimetics (Dwivedi  et  al. 2016). There was 
a significant inhibition of tumor growth of the chemo-
resistant ovarian cancer cells by the addition of the miR 
mimetics that targeted BMI1 and the cisplatin transporter, 
ATP7B (Dwivedi et al. 2016). The study demonstrated that 
in vivo nano-liposomal delivery of miR-15a and miR-16 
decrease tumor growth in preclinical chemo-resistant 
orthotopic ovarian cancer mouse model in support of 
combination therapies. In another study, restoration of 
miR-199b-5p increased sensitivity to cisplatin induced 
cytotoxicity in vitro and in vivo ovarian cancer models via 
inactivation of Jag1 mediated Notch signaling pathway 
(Liu et al. 2014b). A combination therapy possibility with 
miRs and taxane-based chemotherapy was also suggested. 
With the reports miR-200c role in ZEB1/ZEB2-mediated 
EMT progression, Cittelly and coworkers found that 
restoration of miR-200c induced chemo- and ankoikis 
sensitivity (Cittelly  et  al. 2012). Furthermore, miR-220c 
restoration also helped reduce tumor growth alone and 
in combination with paclitaxel (Cittelly et al. 2012). The 
point of this study was to test if the recovery of miR-200c 
can improve response to chemotherapy. Ovarian cancer 
has a high rate of relapse within 18  months of current 
therapeutic interventions with no targeted therapies 
approved. To identify patients that will benefit from 
current lines of chemotherapy, an interventional trial 
profiling serum miRs from patients prior to chemotherapy 
treatment is being performed (ClinicalTrials.gov identifier: 
NCT01391351, Table  2). For those that may not fare as 
well on chemotherapy, miRs may be used to overcome 
drug resistant variants that emerge in ovarian cancer 
progression.
miRs in breast cancer patient care
Breast cancer is the second leading killer of women, with 
only lung cancer resulting in more cancer deaths. Yet, 
more than 3.1 million women with a history of breast 
cancer are alive in the US with the potential need for 
further means of intervention. The estrogen receptor 
positive subtype is a critical discriminator, accounting 
for nearly 75% of all cases of breast cancer. However, 
non-hormone responsive (triple negative breast cancer) 
results account for the poor prognosis, often treated 
with a cytotoxic chemotherapy or/and targeted therapy 
(with exception of HER2 antagonists). As with prostate 
cancer, hormone responsive breast cancer can evolve 
to a hormone-nonresponsive disease in heterogeneous 
tumors. As with other cancers discussed, there is a lack of 
reliable biomarkers for patient selection and therapeutic 
efficacy where miRs can play an important role. Heneghan 
and coworkers demonstrated that among the elevated 
breast cancer-associated miRs present in circulation, 
miR-195 can help distinguish from other malignancies 
(melanoma, renal, prostate and colon cancer) and from 
non-malignant subjects (Heneghan  et  al. 2010). All the 
cancer patients generally expressed let-7a, miR-10b and 
miR-155, but miR-195 provided strong specificity and 
sensitivity with other covariates.
With MXR34 being tested and the breadth of supporting 
literature for its application, many patients including those 
with breast cancer may benefit following pharmacokinetics/
maximum tolerated dose (PK/MTD) are established in the 
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phase I trial. In a recent report, anti-tumorigenic effect of 
miR-34a administration in triple negative breast cancer 
models inhibited proliferation, invasion and metastasis 
(Adams  et  al. 2016). Moreover, the delivery of miR-
34a replacement therapy retarded the tumor growth of 
subcutaneously and orthotopically xenografted tumors 
(Adams et al. 2016). In a seminal publication where breast 
cancer patients were treated with the chemotherapeutic 
5-flurouracil (5-FU), miR-34a was found to be downregulated 
(Li et al. 2013a). Accordingly, a miR-34a mimetic was given 
with chemotherapeutic 5-flurouracil (5-FU) to reveal a more 
efficient anti-tumor effect than either single agent treatment 
(Li et al. 2013a). These studies support the promise of miR-
34a (MXR34) as a potential therapeutic agent for breast and 
other cancer patients.
Majority of the breast cancer clinical trials are 
observational in terms of profiling circulating miR 
expression, like the one by Cancer Trials Ireland which 
aims to identify miR in response to neoadjuvant and 
adjuvant chemotherapy (ClinicalTrials.gov identifier: 
NCT01722851, Table 3). Similarly, another clinical study 
investigates the circulating miRs as markers of hormone 
resistance and sensitivity in patients with metastatic 
invasive breast cancer or locally advanced breast cancer 
(ClinicalTrials.gov identifier: NCT01612871, Table  3). 
It is worth noting the paradigm set by identifying miRs 
as a surrogate of side effect of certain chemotherapies. 
Doxorubicin (Adriamycin, Rubex), used for many cancers 
including breast cancer, is a DNA damaging agent that 
can cause cardiac damage. Years of work on miRs in the 
cardiology field has revealed miR-208 to be elevated in 
cases of cardiac hypertrophy and heart failure (Callis et al. 
2009, Montgomery et al. 2011, Oliveira-Carvalho & Bocchi 
2016). miR-208 expression is associated with fibrosis and 
EMT progression as well as specifically targeting the BMP 
co-receptor, endoglin (Fig. 1) (Liu et al. 2014a, Wang et al. 
2014a). If the clinical trial demonstrates miR-208 
as a robust marker for cardiac damage, there will be a 
pre-clinical basis to consider the use of an antimiR-208 
as a viable cardio-protective for chemotherapy patients 
(Callis  et  al. 2009, Montgomery  et  al. 2011, Tony  et  al. 
2015). Such an application of a miR-based therapy would 
follow the logic of a preclinical study where Xue and 
coworkers identified miR-621 elevation associated with 
paclitaxel and carboplatin (PTX/CBP) sensitivity (Xue et al. 
2016). They subsequently administered miR-621 mimetic 
to silence the FBXO11, a poor prognostic indicator, in 
sensitizing breast tumors to PTX/CBP (Xue  et  al. 2016). 
As most of the miR-associated trials listed in Tables 1, 2 
and 3 are observational, in identifying changes in miR 
expression, this paradigm of targeting the deregulated 
miRs for therapy could follow. With appropriate pre-
clinical validation, these same miRs may be targeted by a 
miR mimetic or anti-miR. However, as with any such line 
of reasoning, not all good biomarkers are consequential 
to disease etiology and conversely, miRs that are central 
to disease progression or therapeutic resistance may not 
serve to be robust biomarkers.
Summary and perspective
Many examples of miR-based biomarkers and potential 
therapeutics in prostate, ovarian and breast cancers 
have been presented. These examples serve to highlight 
the mechanism of action and ongoing clinical trials for 
the diseases. In the post-genomic age a trove of patient/
tumor-specific data can potentially guide and prioritize 
the clinical findings. However, the challenge in the field is 
the ability to predict miR target sites with high confidence 
in a cell type of interest. miRs typically repress target gene 
expression, but the reciprocal effect on targets by miRs is 
less clear. Although miR-based therapeutics is in its infancy 
it faces many of the same limitations as other targeted 
therapies. As the miR field progresses the focus may be less 
Table 2 Ovarian cancer clinical trials involving miRs.
Trial reference Study type Sponsor Trial title
NCT02758652 Observational Tampere University Hospital Molecular mechanisms leading to chemo-resistance 
in epithelial ovarian cancer
NCT01391351 Interventional Centre Francois Baclesse Search for predictors of therapeutic response in 
patients with carcinoma of the ovary, the fallopian 
tube or peritoneal serous-type advanced
NCT01572467 Observational Children’s Oncology Group DICER1 mutations and miRNA in ovarian and 
testicular sex cord stromal tumors of childhood
NCT01970696 Observational Children’s Hospitals and Clinics of Minnesota International ovarian and testicular stromal tumor 
registry
NCT01879436 Observational Meir Medical Center The effect of human placental explants and 
pregnant women sera on cancer cells
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on a specific target, but a genomically defined phenotype. 
Conceptually, miRs could complement CRISPR/Cas9 
in engineering networks. As we better characterize the 
heterogeneous nature of a patient’s tumors and consider 
genetic/epigenetic drift associated with disease progression 
and therapeutic response, miR-based therapies become 
more attractive due to their stability, sequence specificity, 
and relative ease of synthesis.
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Table 3 Breast cancer clinical trials involving miRs.
Trial reference Study type Sponsor Trial title
NCT01722851 Observational Cancer Trials Ireland Circulating miRNAs: novel breast cancer biomarkers and their 
use for guiding and monitoring response to chemotherapy
NCT02127073 Interventional Sheldon Feldman Pilot study of oxytocin and microRNA identification in NAF, 
serum, and tissue in women with breast cancer
NCT01957332 Observational University Medical Center 
Groningen
Imaging patients for cancer drug selection – metastatic breast 
cancer (IMPACT-MBC)
NCT01598285 Observational Spanish Breast Cancer Research 
Group
A combined GWAS and miRNA for the Identification of 
bevacizumab response predictors in metastatic breast cancer
NCT01231386 Observational City of Hope Medical Center miRNAs profiling of breast cancer in patients undergoing 
neoadjuvant or adjuvant treatment for locally advanced and 
inflammatory breast cancer
NCT01612871 Interventional Institut Claudius Regaud Circulating miRNAs as biomarkers of hormone sensitivity in 
breast cancer? Pilot study
NCT02656589 Observational Sun Yat-Sen Memorial Hospital 
of Sun Yat-Sen University
A perspective study of the predictive value of microRNA in 
patients with HER2 positive advanced stage breast cancer who 
were treated with herceptin
NCT02065908 Observational West Pomeranian Cancer Center Circulating microRNAs as a novel biomarker of early 
cardiotoxicity in breast cancer patients treated with 
anthracyclines
NCT00581750 Observational Memorial Sloan Kettering 
Cancer Center
Molecular genetic basis of invasive breast cancer risk associated 
with lobular carcinoma in situ
NCT01965522 Interventional Juravinski Cancer Center Anti-proliferative effects of vitamin D and melatonin in breast 
cancer (MELO-D)
NCT02288806 Interventional Hamilton Health Sciences 
Corporation
Melatonin and vitamin d in breast cancer (MELO-D)
NCT02103140 Interventional Georgetown University An exercise randomized controlled trial targeting African-
American women with metabolic syndrome and high risk for 
breast cancer
NCT01907438 Observational Hadassah Medical Organization Identification of the transformation potential of normal 
estrogen exposed BRCA1 (breast cancer susceptibility gene 1) 
and BRCA2 (breast cancer susceptibility gene 2) heterozygous 
epithelial breast cells due to irradiation
NCT00773695 Interventional Hoffmann-La Roche A multicenter, randomized, ph II clinical trial to evaluate the 
effect of avastin in combination with neoadj treatment 
regimens on the molecular and metabolic characteristics and 
changes in the primary tumors with ref to the obtained 
responses in patients with large primary HER2 Neg breast 
cancers
NCT01724450 Interventional University of Sao Paulo Carvedilol effect in preventing chemotherapy – induced 
cardiotoxicity. a randomized double blind study
NCT02437318 Interventional Novartis Pharmaceuticals A phase III randomized double-blind, placebo controlled study 
of alpelisib in combination with fulvestrant for men and 
postmenopausal women with hormone receptor positive, 
HER2-negative advanced breast cancer which progressed on or 
after aromatase inhibitor treatment
NCT01879436 Observational Meir Medical Center The effect of human placental explants and pregnant women 
sera on cancer cells
NCT02678650 Interventional Capital Medical University MicroRNA mediates volatile anesthetics preconditioning 
induced artery protection
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